Evžen Gregora

558 total citations
29 papers, 301 citations indexed

About

Evžen Gregora is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Evžen Gregora has authored 29 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 15 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Evžen Gregora's work include Multiple Myeloma Research and Treatments (24 papers), Cancer Treatment and Pharmacology (10 papers) and Protein Degradation and Inhibitors (6 papers). Evžen Gregora is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Cancer Treatment and Pharmacology (10 papers) and Protein Degradation and Inhibitors (6 papers). Evžen Gregora collaborates with scholars based in Czechia, United Kingdom and United States. Evžen Gregora's co-authors include Roman Hájek, Petr Kuglík, Luděk Pour, Ivan Špıčka, Jan Smetana, Viera Sandecká, Vladimír Maisnar, Christopher P. Wardell, Brian A. Walker and Martina Almáši and has published in prestigious journals such as Blood, Haematologica and European Journal of Clinical Pharmacology.

In The Last Decade

Evžen Gregora

25 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evžen Gregora Czechia 11 253 218 130 43 28 29 301
A. Keith Stewart United States 5 221 0.9× 184 0.8× 118 0.9× 37 0.9× 12 0.4× 13 257
Edvan de Queiroz Crusoé Brazil 8 229 0.9× 233 1.1× 156 1.2× 33 0.8× 16 0.6× 41 353
Miguel Teodoro Hernández‐Garcia Spain 6 328 1.3× 264 1.2× 168 1.3× 39 0.9× 18 0.6× 10 373
Agne Paner United States 9 160 0.6× 217 1.0× 114 0.9× 31 0.7× 12 0.4× 33 282
Kylee Maclachlan United States 9 168 0.7× 268 1.2× 118 0.9× 19 0.4× 38 1.4× 43 343
Sung‐Soo Yoon South Korea 9 152 0.6× 120 0.6× 91 0.7× 58 1.3× 15 0.5× 54 272
Marti McKinley United States 9 427 1.7× 395 1.8× 283 2.2× 35 0.8× 18 0.6× 17 507
Vladimir Vorobyev Russia 10 228 0.9× 185 0.8× 137 1.1× 85 2.0× 23 0.8× 39 383
D. Carrera Spain 5 239 0.9× 165 0.8× 128 1.0× 35 0.8× 16 0.6× 9 276
Scott VanWier United States 4 209 0.8× 167 0.8× 72 0.6× 49 1.1× 23 0.8× 4 275

Countries citing papers authored by Evžen Gregora

Since Specialization
Citations

This map shows the geographic impact of Evžen Gregora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evžen Gregora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evžen Gregora more than expected).

Fields of papers citing papers by Evžen Gregora

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evžen Gregora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evžen Gregora. The network helps show where Evžen Gregora may publish in the future.

Co-authorship network of co-authors of Evžen Gregora

This figure shows the co-authorship network connecting the top 25 collaborators of Evžen Gregora. A scholar is included among the top collaborators of Evžen Gregora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evžen Gregora. Evžen Gregora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Štork, Martin, Lucie Brožová, Vladimír Maisnar, et al.. (2019). Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data. Neoplasma. 67(1). 178–184.
3.
Hájek, Roman, Jiří Jarkovský, Vladimír Maisnar, et al.. (2018). Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. Clinical Lymphoma Myeloma & Leukemia. 18(6). e219–e240. 18 indexed citations
4.
Radocha, Jakub, Roman Hájek, Lucie Brožová, et al.. (2018). Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis. Annals of Hematology. 98(4). 951–962. 2 indexed citations
5.
Minařík, Jiří, Tomáš Jelı́nek, Alexandra Jungová, et al.. (2018). Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes. Blood. 132(Supplement 1). 1959–1959. 4 indexed citations
6.
Mikulášová, Aneta, Christopher P. Wardell, Alexander Murison, et al.. (2017). The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 102(9). 1617–1625. 64 indexed citations
7.
Mikulášová, Aneta, Jan Smetana, Viera Sandecká, et al.. (2016). Genomewide profiling of copy‐number alteration in monoclonal gammopathy of undetermined significance. European Journal Of Haematology. 97(6). 568–575. 25 indexed citations
8.
9.
Štraub, Jan, Roman Hájek, Vladimír Maisnar, et al.. (2014). Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). Blood. 124(21). 5682–5682. 1 indexed citations
10.
Němec, Pavel, Zuzana Zemanová, Petr Kuglík, et al.. (2011). Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leukemia & lymphoma. 53(5). 920–927. 34 indexed citations
11.
Krejčí, Marta, Evžen Gregora, Jan Štraub, et al.. (2011). Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Annals of Hematology. 90(12). 1441–1447. 2 indexed citations
12.
Štraub, Jan, et al.. (2009). Mnohočetný myelom - časná diagnostika. 6(4). 197–199.
13.
Němec, Pavel, Zuzana Zemanová, Henrieta Grešlíková, et al.. (2009). Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy. Biology of Blood and Marrow Transplantation. 16(4). 548–554. 54 indexed citations
14.
Maisnar, Vladimír, Roman Hájek, Vlastimil Ščudla, et al.. (2007). High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplantation. 41(1). 51–54. 14 indexed citations
15.
Hájek, Roman, et al.. (2005). [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].. PubMed. 144(9). 636, 638–40. 4 indexed citations
16.
Klézl, Zdeněk, Martin Krbec, Evžen Gregora, & J Stříteský. (2002). Rare presentation of non-Hodgkin lymphoma of the thoracolumbar spine in pregnancy with 7 years' survival. Archives of Orthopaedic and Trauma Surgery. 122(5). 308–310. 3 indexed citations
17.
Pytlík, Robert, Evžen Gregora, Petr Beneš, & Tomáš Kozák. (2002). [Effect of parenteral glutamine on restoration of lymphocyte subpopulations after high-dose chemotherapy and autologous hematopoietic cell transplantation: data from a double-blind randomized study].. PubMed. 51(4). 152–5. 4 indexed citations
18.
Thürmann, Petra, et al.. (2001). Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. European Journal of Clinical Pharmacology. 57(3). 235–241. 13 indexed citations
19.
Jirsa, M, et al.. (2000). [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].. PubMed. 139(7). 208–12. 1 indexed citations
20.
Kozák, Tomáš, Eva Havrdová, Jiří Piťha, et al.. (2000). [Immunoablation and hematopoietic stem cell transplantation in the treatment of multiple sclerosis].. PubMed. 139(9). 263–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Edvan de Queiroz Crusoé Breakdown of academic impact, for papers by Miguel Teodoro Hernández‐Garcia Breakdown of academic impact, for papers by Agne Paner Breakdown of academic impact, for papers by Kylee Maclachlan Breakdown of academic impact, for papers by Sung‐Soo Yoon Breakdown of academic impact, for papers by Marti McKinley Breakdown of academic impact, for papers by Vladimir Vorobyev Breakdown of academic impact, for papers by D. Carrera Breakdown of academic impact, for papers by Scott VanWier
Rankless by CCL
2026